Population Pharmacokinetic Data Analysis of Cilobradine, an If Channel Blocker
- 96 Downloads
To evaluate the population pharmacokinetic characteristics of cilobradine including a covariate analysis based on six phase I trials and to assess the predictive performance of the model developed.
Single or multiple doses of cilobradine were administered as solution, capsule or infusion. Two thousand, seven hundred and thirty-three plasma samples (development data set) were used for model development in NONMEM. Model evaluation was performed using also an external data set.
Data were best described by a linear three-compartment model. Typical Vss was large (∼100 l) and CL was 21.5 l/h. Covariate analysis revealed a statistically significant but clinically irrelevant relation between KA and dose. Inter-individual variability was moderate (15–46%); imprecision of estimates was generally low. The final model was successfully applied to the external data set revealing its robustness and general applicability. Its final estimates resembled those of the development data set except for the covariate relation not being supported. When excluding the covariate relation, all observations were well predicted.
A robust population PK model has been developed for cilobradine predicting plasma concentrations from a different study design well. Therefore, the model can serve as a tool to simulate and evaluate different dosing regimens for further clinical trials.
Key wordscilobradine If channel blocker NONMEM population pharmacokinetics
- 3.W. H. Frishman. Beta-adrenergic blockade for the treatment of angina pectoris. In D. A. Weiner and W. H. Frishman (eds.), Therapy of Angina pectoris. A Comprehensive Guide for the Clinicians, Marcel Dekker, New York, 1986, pp. 83–144.Google Scholar
- 15.W. H. Frishman, C. J. Pepine, R. J. Weiss, and W. M. Baiker. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The Zatebradine Study Group. J. Am. Coll. Cardiol. 26(2):305–312 (1995).PubMedCrossRefGoogle Scholar
- 19.S. L. Beal and L. B. Sheiner. NONMEM Users Guide, NONMEM project group, University of Carlifornia, San Francisco, CA, 1992.Google Scholar
- 26.Center for Drug Evaluation and Research (C.D.E.R.). Population Pharmacokinetics, Guidance for Industry, Rockville, 1999.Google Scholar
- 31.W. Roth, E. Bauer, G. Heinzel, P. J. Cornelissen, R. G. van Tol, J. H. Jonkman, and P. B. Zuiderwijk. Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. J. Pharm. Sci. 82(1):99–106 (1993).PubMedCrossRefGoogle Scholar
- 32.I. Ragueneau, C. Laveille, R. Jochemsen, G. Resplandy, C. Funck-Brentano, and P. Jaillon. Pharmacokinetic–pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin. Pharmacol. Ther. 64(2):192–203 (1998).PubMedCrossRefGoogle Scholar
- 34.R. Savic, D. M. Jonker, T. Kerbusch, and M. O. Karlsson. Evaluation of a transit compartment model versus lag time model for describing drug absorption delay. 13th Population Approach Group Europe Meeting, Uppsala, Sweden, Abstract 513 (2004).Google Scholar